ARTICLE | Clinical News
Injectable BB-882: Began Phase II trials
May 3, 1993 7:00 AM UTC
British Bio-technology Group plc (BBIOY) Product: Injectable BB-882 Platelet Activating Factor (PAF) antagonist Indication: Sepsis Status: Began Phase II trials in the U.K. ...